Table 1 Patients characteristics
N | % | |
|---|---|---|
Age Median: 59 y (37–84) | ||
Cycles of CT: 3 (1–7) | ||
BM | 22 | 100 |
Parenchymal | 17 | 77 |
Leptomeningeal | 8 | 36 |
Lines prior of CT | ||
≤ 3 | 8 | 36 |
> 3 | 14 | 64 |
HER-2 status | ||
Positive | 13 | 59 |
Negative | 8 | 36 |
Not Known | 1 | 5 |
Hormone Receptors status | ||
Positive | 11 | 50 |
Negative | 10 | 45 |
Not Known | 1 | 5 |
Triple Negative | 2 | 9 |
CNS Radiotherapy | ||
Yes | 15 | 68 |
No | 7 | 32 |
Other site of metastases | ||
Yes | 20 | 81 |
No | 2 | 9 |
Concomitant treatment | ||
Yes | 14 | 64 |
Trastuzumab intravenous | 11 | 50 |
MTX intrathecal | 2 | 9 |
Lapatinib | 1 | 5 |
No | 7 | 32 |